Mon, May 26, 2025
[Archive]
.png)
Volume 4, Issue 1 (3-2018)
jhehp 2018, 4(1): 20-25 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Firouzkouhi Moghaddam M, Rakhshani T, Kadkhodaie F, Rashki M. Methadone and Buprenorphine for the Treatment of Opiate Addiction. jhehp 2018; 4 (1) :20-25
URL: http://jhehp.zums.ac.ir/article-1-147-en.html
URL: http://jhehp.zums.ac.ir/article-1-147-en.html
1- Research Center for Health of Adolescents and Children, Zahedan University of Medical Sciences, Zahedan, Iran.
2- Nutrition Research Center , School of Health , Shiraz University of Medical Science ,Shiraz , Iran.
3- Department of Public Health , School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
2- Nutrition Research Center , School of Health , Shiraz University of Medical Science ,Shiraz , Iran.
3- Department of Public Health , School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract: (8608 Views)
Background: The rate of drug dependence and abuse is a growing problem in the Iran, number of opioid – dependent people is estimated at a total of 2000.000-4000.000 individuals. The aim of this study was a Comparison of Methadone and Buprenorphine in the Treatment of Opiate Addiction referring to a treatment clinic of Baharan psychiatric hospital in Zahedan city.
Methods: In a cross sectional study, 152 patients with opioid dependence were assigned into two treatment groups i.e. Methadone and Buprenorphine. Data were collected from patients using a questionnaire COWS. ANOVA and repeated measures regressions were used to evaluate the significant differences on using drug (methadone and Buprenorphine), time, and drug-by-time interaction terms.
Results: Patients on MMT and BMT differed in terms of Age started addiction (P = 0.0001); education level (P = 0.0001); and income (P = 0.0001), and no differed in term of sex (P = 0.8). There was no significant difference between the two groups taking buprenorphine and methadone (P = 0.87).
Conclusion: In conclusion, our study indicated, Buprenorphine and methadone are both proven to be effective treatment options.
Methods: In a cross sectional study, 152 patients with opioid dependence were assigned into two treatment groups i.e. Methadone and Buprenorphine. Data were collected from patients using a questionnaire COWS. ANOVA and repeated measures regressions were used to evaluate the significant differences on using drug (methadone and Buprenorphine), time, and drug-by-time interaction terms.
Results: Patients on MMT and BMT differed in terms of Age started addiction (P = 0.0001); education level (P = 0.0001); and income (P = 0.0001), and no differed in term of sex (P = 0.8). There was no significant difference between the two groups taking buprenorphine and methadone (P = 0.87).
Conclusion: In conclusion, our study indicated, Buprenorphine and methadone are both proven to be effective treatment options.
Type of Study: Original Article |
Subject:
Public Health
Received: 2017/12/10 | Accepted: 2018/02/17 | Published: 2018/03/21
Received: 2017/12/10 | Accepted: 2018/02/17 | Published: 2018/03/21
References
1. AlamMehrjerdi Z, Abarashi Z, Mansoori S, Deylamizadeh A, SalehiFadardi J, Noroozi A, et al. Methamphetamine Use Among Iranian Heroin Kerack-Dependent Women: Implications for Treatment. Int J High Risk Behav Addict. 2013; 2(1): 15-21. [Crossref]
2. Sarami H, GHorbani M, Minoei M. Prevalence of Addiction in Iran Four Decades of Research. Q J Res Addict. 2013; 7(26): 29-52.
3. Nouri R, Sedighian A, Rafie H, Narengiha H, Sarrami , Baghestani A. Analysis of Trends in Abuse during the Past Two Decades [Research Project]. Tehran: Soc Welf Rehabil Sci; 2009.
4. United Nations Office on Drugs and Crime (UNODC). World Drug Report. New York: UNODC; 2013.
5. Doaaagoyan D, Habibzadeh A. Factors Affecting the Changing Patterns of abuse among Youth (Lighter Materials to Heavy Materials). Quarterly knowledge Disciplinary. 2012; 13(1): 106-33.
6. Jadidi M. A Review of Drug Dependence, Proceedings of the First International Conference of Applied Science to Improve Social Security. Iran: Express Publications Gorgan Rahman; 2008.
7. Rassool G. Addiction for Nurses. Chichester, West Sussex. London: Wiley-Blackwell; 2010. [Crossref]
8. Papadakis MA, McPhee SJ. Current Medical Diagnosis and Treatment. New York: McGraw Hill; 2014.
9. Tai B, Saxon AJ, Ling W. Medication-Assisted Therapy for Opioid Addiction. J Food Drug Anal. 2013; 21(4): S13-S 15.
10. Bart G. Maintenance Medication for Opiate Addiction: The Foundation of Recovery. J Addict Dis. 2012; 31(3): 207-25. [Crossref]
11. Crowley RA, Kirschner N. The Integration of Care for Mental Health, Substance Abuse, and Other Behavioral Health Conditions into Primary Care: Executive Summary of an American College of Physicians Position Paper. Ann Intern Med. 2015; 163(4): 298-9. [Crossref]
12. Peddicord AN, Bush C, Cruze C. A Comparison of Suboxone and Methadone in the Treatment of Opiate Addiction. J Addict Res Ther. 2015; 6: 248. [Crossref]
13. Mauger S, Fraser R, Gill K. Utilizing Buprenorphine–Naloxone to treat illicit and Prescription-opioid Dependence. Neuropsychiatr Dis Treat. 2014; 10: 587-98.
14. Clausen T, Anchersen K, Waal H. Mortality Prior to, During and after Opioid Maintenance Treatment (OMT): A National Prospective Cross-Registry Study. Drug Alcohol Depend. 2008; 94: 151–7. [Crossref]
15. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of Death During and after Opiate Substitution Treatment in Primary Care: Prospective Observational Study in UK General Practice Research Database. BMJ. 2010; 341: c5475. [Crossref]
16. Bell J, Byron G, Gibson A, Morris A. A Pilot Study of Buprenorphine-naloxone Combination Tablet (Suboxone) in Treatment of Opioid Dependence. Drug Alcohol Review. 2004; 23(3): 311–7. [Crossref]
17. Mattick RP, Breen C, Kimber J, Davoli M. Methadone Maintenance Therapy Versus no Opioid Replacement Therapy for Opioid Dependence. Cochrane Database Syst Rev. 2014; 3.
18. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003; 35(2): 253-9. [Crossref]
19. Papadakis MA, McPhee SJ. Current Medical Diagnosis and Treatment. New York: McGraw Hill; 2014.
20. Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, et al. A Multi-Site Comparison of Psychosocial Approaches for the Treatment of Methamphetamine Dependence. Addict. 2004; 99(6): 708-17. [Crossref]
21. Mee-Lee D, Shulman GD, Fishman MJ, Gastfriend DR, Miller MM, eds. The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions. 3rd ed. Carson City, NV: The Change Companies; 2013.
22. Day E, Strang J. Outpatient versus Inpatient Opioid Detoxification: A Randomized Controlled Trial. J Subst AbuseTreat. 2011; 40(1): 56-66. [Crossref]
23. Chalk M, Alanis-Hirsch K, Woodworth A, et al. FDA Approved Medications for the Treatment of Opiate Dependence: Literature Reviews on Effectiveness and Cost-Effectiveness. 2013. Available from: URL: http://www.asam.org/docs/advocacy/Implications-for-Opioid-Addiction-Treatment.
24. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs. Methadone Maintenance treatment for Concurrent Opioid Dependence and Cocaine Abuse. Arch Gen Psychiatry. 1997; 54(8): 713–20. [Crossref]
25. Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among Regular or Dependent Users of Heroin and other Opioids: A Systematic Review and Meta‐Analysis of Cohort Studies. Addict. 2011; 106(1): 32-51. [Crossref]
26. Mattick RP, Breen C, Kimber J, Davoli M. Methadone Maintenance Therapy Versus no Opioid Replacement Therapy for Opioid Dependence. Cochrane Database Syst Rev. 2009; 3. [Crossref]
27. Petitjean S, Stohler R, Deglon, JJ, Livoti S, Waldvogel D, Uehlinger C, et al. Double-blind Randomized Trial of Buprenorphine and Methadone in Opiate Dependence. Drug Alcohol Depend. 2001; 62(1): 97-104. [Crossref]
28. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence. N Engl J Med. 2000; 343(2): 1290-97. [Crossref]
29. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, et al. A Multi-Center Randomized Trial of Buprenorphine-naloxone Versus Clonidine for Opioid Detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addict. 2005; 100: 1090-100. [Crossref]
30. Pani PP, Maremmanim I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: A Controlled Clinical Trial in the Treatment of Opioid Dependence. Drug Alcohol Depend. 2000; 60(1): 39-50. [Crossref]
31. Marco A, Lopez-Burgos A, Garcia-Marcos L, Gallego C, Anton JJ, Errasti A. Is the Availability of Buprenorphine/naloxone Therapy for Opioid-Dependent Inmates a Necessity? Rev Esp Sanid Penit. 2013; 15: 105-13. [Crossref]
32. Johnson RE, Jaffe JH, Fudala PJ. A Controlledtrial of Buprenorphine Treatment for Opioid Dependence. JAMA.1992; 267(20): 2750-55. [Crossref]
33. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus Methadone in the Treatment of Opioid Dependent Cocaine Users. Psychopharmacol. 1994a; 116(4): 401–6. [Crossref]
34. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of Buprenorphine and Methadone in the Treatment of Opioid Dependence. JAMA Psychiatry. 1994b; 151: 1025-30.
35. Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stuhlinger G, Pezawas L, Aschauer HN, Kasper S. Buprenorphine Versus Methadone Maintenance for the Treatment of Opioid Dependence. Addict. 1999; 94(9): 1337-47. [Crossref]
36. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus Methadone Maintenance for Opioid Dependence. J Nerv Ment Dis. 1993; 181: 358-64. [Crossref]
37. Oliveto AH, Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Cocaine Use in Buprenorphine- vs. Methadone-Maintained Patients. Am J Addict. 1994; 3: 43-8. [Crossref]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
© 2024 The Author(s)
